Comparison of Pharmacokinetics of and Effect on Systemic Vascular Endothelial Growth Factor (VEGF) Levels Over Time of Intravitreal Ranibizumab and Bevacizumab and Aflibercept in Age Related Macular Degeneration Patients
Phase of Trial: Phase II/III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 10 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
- 10 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.